ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

about

Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk

P2860

Q58791244-40FB8D0E-05C7-48BE-A89C-5595922FCAA7

P2860

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

Item

http://www.wikidata.org/entity/Q42143934

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@en

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@nl

type

Item

label

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@en

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@nl

prefLabel

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@en

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@nl

P1476

ERCC1 Expression in Metastatic ...... th Platinum-Based Chemotherapy

@en

P2093

Mohamed Ali EL Baiomy

http://www.w3.org/2001/XMLSchema#string

Wagdi F El Kashef

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Triple-negative breast cancer: an unmet medical need

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes

The resurgence of platinum-based cancer chemotherapy.

Triple-negative breast cancer: clinical features and patterns of recurrence.

P304

507-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2017.18.2.507

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28345838

http://www.w3.org/2001/XMLSchema#string

P932

5454751

http://www.w3.org/2001/XMLSchema#string

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

about

P2860

P2860

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932